Abstract 530: Evaluation of in vitro invasion of primary vs recurrent glioblastoma multiforme cells using organotypic rodent brain slice culture

Abstract

Abstract Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the adult central nervous system. The highly lethal nature of this tumor partly derives from the acquisition of an invasive phenotype, which allows the tumor cells to infiltrate the surrounding brain tissues. In fact the tumor cells, leading to the recurrence of the primary neoplasm highly contribute to the lack of success in eradicating this disease. In order to measure the migrating ability of GBM cells and the potential difference in infiltration capacity of primary versus recurrent GBM cells, we developed and validated an organotypic rodent brain slice assay and visualized the fluorescently labeled cells using confocal laser scanning microscopy. The invasion capacity has been quantified applying an innovative image analysis method using a panel of primary and recurrent glioma cell lines derived from patient biopsies and the commercially available GBM cell lines, DBTRG-05MG (recurrent) and T98G (primary). For validation purposes, cytochalasin D, a potent inhibitor of actin polymerization and hence migration and invasion, was used. The results revealed clear differences between primary and recurrent GBM cells: They differ both in their migrating capacity on the surface of the brain slice as well as by their ability to invade into the brain slice. A small population of recurrent GBM cells seems to acquire high infiltrative capacity allowing the invasion of brain tissue to greater distance than the primary GBM cells. Higher invasiveness may be an important characteristic of recurrent tumours, adding to our understanding of their worse clinical evolution and responsiveness to therapy. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 530.